Generic placeholder image

Mini-Reviews in Medicinal Chemistry


ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

On The Edge of Validation – Cancer Protease Fibroblast Activation Protein

Author(s): Beni B. Wolf, Clifford Quan, Thuy Tran, Christian Wiesmann and Daniel Sutherlin

Volume 8, Issue 7, 2008

Page: [719 - 727] Pages: 9

DOI: 10.2174/138955708784567449

Price: $65


Numerous studies implicate the prolyl peptidase, fibroblast activation protein (FAP) in tumorigenesis; however, FAP-selective inhibitors have not yet been developed to fully validate FAP as a therapeutic target. Herein, we review recent efforts aimed at validating and inhibiting FAP for cancer therapy and highlight future directions for successful targeting of this prolyl peptidase.

Keywords: FAP, DPP4, dipeptidyl peptidase, prolyl peptidase, inhibitor, cancer

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy